Valuation: Roche Holding AG

Market Cap 321B 390B 348B 291B 551B 36,579B 565B 3,834B 1,528B 19,583B 1,465B 1,433B 61,680B P/E 2026 *
21.6x
P/E 2027 * 19.5x
Enterprise Value 332B 405B 361B 302B 571B 37,917B 586B 3,975B 1,584B 20,300B 1,518B 1,486B 63,935B EV / Sales 2026 *
5.24x
EV / Sales 2027 * 4.92x
Free-Float
88.78%
Yield 2026 *
2.5%
Yield 2027 * 2.56%
Manager TitleAgeSince
Chief Executive Officer 51 14/03/2023
Director of Finance/CFO 59 05/06/2011
Chief Operating Officer - 30/09/2025
Director TitleAgeSince
Director/Board Member 68 31/12/1995
Chairman 59 14/03/2023
Director/Board Member 73 02/03/2015
Change 5-day change 1-year change 3-year change Capi.($)
-1.35%+2.01% - - 381B
+4.28%+0.07%+52.75%+138.78% 1,206B
+2.13%+4.27%+51.21%+91.36% 665B
+0.68%+1.54%+33.83%+112.47% 515B
+2.77%+0.98%+49.44%+68.46% 381B
+1.38%+0.27%+72.42%+45.30% 362B
+0.29%+1.48%+30.84%+58.32% 307B
+0.98%+1.49%+9.04%+34.78% 289B
+1.04%-0.05%+45.29%+76.18% 249B
+1.46%-0.59%+42.48%+125.82% 207B
Average +1.40%+0.36%+43.03%+83.50% 464B
Weighted average by Cap. +1.99%+0.65%+45.99%+96.04%

Financials

2026 *2027 *
Net sales 63.41B 77.2B 68.91B 57.55B 109B 7,236B 112B 759B 302B 3,874B 290B 284B 12,202B 66.17B 80.56B 71.91B 60.06B 114B 7,552B 117B 792B 316B 4,043B 302B 296B 12,733B
Net income 14.99B 18.25B 16.29B 13.61B 25.79B 1,711B 26.43B 179B 71.48B 916B 68.51B 67.05B 2,885B 16.59B 20.2B 18.03B 15.06B 28.54B 1,894B 29.25B 198B 79.12B 1,014B 75.83B 74.21B 3,193B
Net Debt 11.72B 14.27B 12.74B 10.64B 20.16B 1,338B 20.66B 140B 55.9B 716B 53.57B 52.43B 2,256B 5.25B 6.39B 5.71B 4.77B 9.03B 599B 9.26B 62.81B 25.03B 321B 23.99B 23.48B 1,010B
Logo Roche Holding AG
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
AA
MarketScreener Ratings - Roche Holding AG